Open-Label, Phase II Study to Assess the Efficacy and Safety of Canakinumab Treatment in Active Hyperimmunoglobulinemia D With Periodic Fever Syndrome Academic Article uri icon

Overview

MeSH Major

  • Antibodies, Monoclonal
  • Mevalonate Kinase Deficiency

abstract

  • The results of this study demonstrate the efficacy and safety of canakinumab treatment to control active HIDS and to suppress inflammation-related transcriptional responses.

publication date

  • August 2017

Research

keywords

  • Academic Article

Identity

Language

  • eng

Digital Object Identifier (DOI)

  • 10.1002/art.40146

PubMed ID

  • 28482144

Additional Document Info

start page

  • 1679

end page

  • 1688

volume

  • 69

number

  • 8